Latest in Cardiology from ACC.org

• Omny-IRE: Novel OMNYPULSE Catheter Effective, Safe in Treatment of Paroxysmal AFib
  The OMNYPULSE pulsed field ablation (PFA) catheter had a 100% acute success rate, paired with a strong safety profile, in treating paroxysmal atrial fibrillation (AFib), according to the three-month results of the Omny-IRE trial presented as a late-breaking trial...
• Pregnant Women With Mechanical Heart Valves Face Greater Health Risks
  Women with a mechanical prosthetic heart valve were at greater risk of pregnancy complications compared with women with a biological valve, based on findings from the ROPAC III study published April 16 in the European Heart Journal.
• ACC CardiaCast: Courtside with the Chair: Discussion on 2025 Sports Eligibility Guidelines - Part 2
  In this episode, Dr. Jonathan Kim is joined by Drs. Baggish, Levine, and Martinez to continue their deep dive into the recently released 2025 Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.
• Pulsed Field Ablation Noninferior to Cryoablation For Paroxysmal AFib
  Pulsed field ablation (PFA) is noninferior to cryoablation for the incidence of a first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation (AFib), according to results from the SINGLE SHOT CHAMPION trial...
• Sharp Increase in Use of Tirzepatide, GLP1 RAs and SGLT2 inhibitors, As Conventional Alternatives Decline
  Among adults with type 2 diabetes (T2D), the use of tirzepatide along with GLP-1 RAs and SGLT2 inhibitors as glucose-lowering medication (GLM) has increased sharply, along with an increased use of tirzepatide and GLP-1 RAs as weight-lowering medication (WLM)...